AU2013276470B2 - Method for quantifying immune cells in tumoral tissues and its applications - Google Patents

Method for quantifying immune cells in tumoral tissues and its applications Download PDF

Info

Publication number
AU2013276470B2
AU2013276470B2 AU2013276470A AU2013276470A AU2013276470B2 AU 2013276470 B2 AU2013276470 B2 AU 2013276470B2 AU 2013276470 A AU2013276470 A AU 2013276470A AU 2013276470 A AU2013276470 A AU 2013276470A AU 2013276470 B2 AU2013276470 B2 AU 2013276470B2
Authority
AU
Australia
Prior art keywords
cells
tumour
stained
value
stained cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013276470A
Other languages
English (en)
Other versions
AU2013276470A1 (en
Inventor
Jerome Galon
Bernhard Mlecnik
Franck Pages
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Cite filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of AU2013276470A1 publication Critical patent/AU2013276470A1/en
Application granted granted Critical
Publication of AU2013276470B2 publication Critical patent/AU2013276470B2/en
Assigned to ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Universite De Paris reassignment ASSISTANCE PUBLIQUE HOPITAUX DE PARIS Request for Assignment Assignors: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES
Assigned to ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PARIS CITÉ reassignment ASSISTANCE PUBLIQUE HOPITAUX DE PARIS Request to Amend Deed and Register Assignors: UNIVERSITÉ PARIS, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2013276470A 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications Ceased AU2013276470B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2012/001446 2012-06-14
IB2012001446 2012-06-14
PCT/EP2013/062405 WO2013186374A1 (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Publications (2)

Publication Number Publication Date
AU2013276470A1 AU2013276470A1 (en) 2014-11-27
AU2013276470B2 true AU2013276470B2 (en) 2018-06-07

Family

ID=46881097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013276470A Ceased AU2013276470B2 (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Country Status (13)

Country Link
US (1) US10317408B2 (https=)
EP (1) EP2861986B1 (https=)
JP (1) JP6449765B2 (https=)
KR (1) KR102179848B1 (https=)
CN (1) CN104541167B (https=)
AU (1) AU2013276470B2 (https=)
BR (1) BR112014031143B8 (https=)
CA (1) CA2873278C (https=)
DE (1) DE13731071T1 (https=)
ES (1) ES2902879T3 (https=)
IL (1) IL235738B (https=)
SG (1) SG11201408107RA (https=)
WO (1) WO2013186374A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2940115C (en) 2014-02-24 2023-03-14 Ventana Medical Systems, Inc. Methods, kits, and systems for scoring the immune response to cancer by simultaneous detection of cd3, cd8, cd20 and foxp3
WO2016034655A2 (en) * 2014-09-03 2016-03-10 Ventana Medical Systems, Inc. Systems and methods for generating fields of view
US11275080B2 (en) 2014-11-05 2022-03-15 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block PD1/PDL1 axis
CA2973878A1 (en) 2015-01-22 2016-07-28 University Of Massachusetts Cancer immunotherapy
US10705088B2 (en) * 2015-10-23 2020-07-07 Novartis Ag Method of scoring a sample comprising tumor tissue
EP3455631B1 (en) * 2016-05-09 2020-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for classifying patients with a solid cancer
EP3889893B1 (en) * 2016-05-18 2022-03-30 F. Hoffmann-La Roche AG Tumor proximity measure
WO2018027223A1 (en) * 2016-08-05 2018-02-08 Duke University Camkk2 inhibitor compositions and methods of using the same
EP3532984B1 (en) * 2016-10-27 2024-05-08 Koninklijke Philips N.V. Apparatus for determining cellular composition information in one or more tissue samples
US11459568B2 (en) 2016-10-31 2022-10-04 University Of Massachusetts Targeting microRNA-101-3p in cancer therapy
CN106846310A (zh) * 2017-01-19 2017-06-13 宁波江丰生物信息技术有限公司 一种基于免疫组化技术的病理辅助分析方法
EP3659110A1 (en) * 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
ES2965647T3 (es) 2018-01-31 2024-04-16 Ventana Med Syst Inc Procedimientos y sistemas para la evaluación de infiltrado de células inmunitarias en cáncer colorrectal en estadio III
WO2020161125A1 (en) * 2019-02-05 2020-08-13 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iv colorectal cancer
SG11202112712RA (en) 2019-06-03 2021-12-30 Inst Nat Sante Rech Med Methods for modulating a treatment regimen
WO2021092071A1 (en) 2019-11-07 2021-05-14 Oncxerna Therapeutics, Inc. Classification of tumor microenvironments
CN111551546B (zh) * 2020-06-01 2023-01-03 南京瑟斯检测科技有限公司 一种基于光学微腔结构超材料的免疫组化便捷检测方法
EP4172628A1 (en) * 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
US20230235408A1 (en) 2020-06-30 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
TWI838687B (zh) * 2021-01-30 2024-04-11 奇美醫療財團法人奇美醫院 評估腫瘤標本免疫狀態的方法
CN113092202A (zh) * 2021-03-25 2021-07-09 上海福君基因生物科技有限公司 一种胃癌预后预测装置
CN113515077A (zh) * 2021-04-23 2021-10-19 重庆德方信息技术有限公司 人体细胞染色过程监控系统及方法
JP2024530213A (ja) 2021-08-10 2024-08-16 ルニット・インコーポレイテッド 病理スライド画像に関する情報を出力する方法及び装置
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
CN116646088B (zh) * 2023-07-27 2023-12-01 广东省人民医院 一种预测方法、装置、设备及介质

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007045996A1 (en) * 2005-10-19 2007-04-26 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69627183T2 (de) * 1995-11-30 2004-01-29 Chromavision Med Sys Inc Verfahren zur automatischen bildanalyse biologischer proben
ES2593930T3 (es) * 2005-12-19 2016-12-14 Ventana Medical Systems, Inc. Impresión automatizada de etiquetas para portaobjetos de especímenes de tejido
JP5551702B2 (ja) * 2008-09-16 2014-07-16 ヒストロックス，インコーポレイテッド． バイオマーカー発現の再現性のある定量
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007045996A1 (en) * 2005-10-19 2007-04-26 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Also Published As

Publication number Publication date
JP2015525349A (ja) 2015-09-03
JP6449765B2 (ja) 2019-01-09
KR20150023760A (ko) 2015-03-05
BR112014031143A2 (pt) 2017-08-08
US20150153349A1 (en) 2015-06-04
IL235738A0 (en) 2015-01-29
US10317408B2 (en) 2019-06-11
WO2013186374A1 (en) 2013-12-19
IL235738B (en) 2019-02-28
AU2013276470A1 (en) 2014-11-27
BR112014031143B1 (pt) 2022-03-03
BR112014031143B8 (pt) 2022-11-22
CN104541167B (zh) 2018-05-01
CN104541167A (zh) 2015-04-22
EP2861986B1 (en) 2021-11-10
EP2861986A1 (en) 2015-04-22
ES2902879T3 (es) 2022-03-30
CA2873278A1 (en) 2013-12-19
DE13731071T1 (de) 2016-08-18
SG11201408107RA (en) 2015-01-29
KR102179848B1 (ko) 2020-11-17
CA2873278C (en) 2021-10-26

Similar Documents

Publication Publication Date Title
AU2013276470B2 (en) Method for quantifying immune cells in tumoral tissues and its applications
KR102502745B1 (ko) 고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치
Bilous et al. Current perspectives on HER2 testing: a review of national testing guidelines
JP6405319B2 (ja) 乳癌予知のための画像分析
Lloyd et al. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it?
US20110111435A1 (en) Detecting Cell Surface Markers
EP3117259B1 (en) Assessment of staining quality
JP5866362B2 (ja) 画像解析による固形腫瘍進行の予後検査
Dobson et al. Image analysis as an adjunct to manual HER‐2 immunohistochemical review: a diagnostic tool to standardize interpretation
Sode et al. Digital image analysis and assisted reading of the HER2 score display reduced concordance: pitfalls in the categorisation of HER2‐low breast cancer
US20240310379A1 (en) A method for measuring a prognostic marker in prostate cancer or in breast cancer
Moelans et al. Validation of a fully automated HER2 staining kit in breast cancer
CN113075408A (zh) 一种利用组蛋白作为内参的免疫组织化学定量方法
WO2025049926A1 (en) Methods of selecting treatment options for cancer
WO2024194834A1 (en) Method and kit for the diagnosis of oral carcinoma
CN115602313A (zh) 用于疾病疗效与生存预后预测的生物标志物及其用途
Pinder et al. HER2 testing in the UK: further update to

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: UNIVERSITE DE PARIS

Free format text: FORMER OWNER(S): INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; UNIVERSITE PARIS DESCARTES

Owner name: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

Free format text: FORMER OWNER(S): INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; UNIVERSITE PARIS DESCARTES

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER OWNER(S): INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; UNIVERSITE PARIS DESCARTES

HB Alteration of name in register

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER NAME(S): ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS

Owner name: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

Free format text: FORMER NAME(S): ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS

Owner name: UNIVERSITE PARIS CITE

Free format text: FORMER NAME(S): ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS

MK14 Patent ceased section 143(a) (annual fees not paid) or expired